source
- Madrigal spends $255 million on multiple MASH drug deals to complement RezdiffraMadrigal Pharmaceuticals is expanding its MASH pipeline by acquiring several assets that could be used alongside its lead candidate, Rezdiffra. In early 2026 the company paid $50 million to Pfizer…
- Novo Nordisk's ziltivekimab fails phase 3 trial, jeopardizing CKD programNovo Nordisk reported that its phase 3 Zeus trial of the IL‑6 ligand antibody ziltivekimab did not meet its primary endpoint, a setback for the drug's development. The study enrolled more than 6,3…